Treatment of leishmaniasis in HIV-positive patients

References

• Albrecht, H., Stellbrink, H. J., Gross, G., Berg, B., Helmchen, U. & Mensing, H. (1994). Treatment of atypical leishmaniasis with interferon-7 resulting in progression of Kaposi's sarcoma in an AIDS patient. Clinical Investigation, 72, 1041–1047.
   PubMedGoogle Scholar
• Altés, J., Salas, A., Riera, M., Udina, M., Galmés, A., Balazant, J., Ballesteros, A., Buades, J., Salvd, F. & Villalonga, C. (1991). Visceral leishmaniasis: another HIV-associated opportunistic infection? Report of eight cases and review of the literature. AIDS, 5, 201–207.
   PubMed Web of Science ®Google Scholar
• Alvar, J., Verdejo, J., Osuna, J. & Najera, R. (1987). Visceral leishmaniasis in a patient seropositive for HIV. European Journal of Clinical Microbiology, 6, 604–606.
   PubMedGoogle Scholar
• Alvar, J., Cahavate, C., Gutierrez-Solar, B., Jimenez, M. I., Laguna, F., LOpez-Vélez, R., Molina, R. & Moreno, J. (1997). Leishmania and human immuno-deficiency virus coinfection: the first 10 years. Clinical Microbiology Reviews, 10, 298–319.
   PubMed Web of Science ®Google Scholar
• Berenguer, J., Moreno, S., Cercenado, E., Bernaldo de Quire, J. C. L., Garcia de la Fuente, A. & Bouza, E. (1989). Visceral leishmaniasis in patients infected with human immunodeficiency virus (HIV). Annals of Internal Medicine, 111, 129–132.
   Google Scholar
• Berman, J. D., Badaró, R., Thakur, C. P., Wasunna, K. M., Behbehani, K., Davidson, R., Kuzoe, F., Pang, L., Weerasuriya, K. & Bryceson, A. D. M. (1998). Efficacy and safety of liposomal amphotericin (AmBisome) for visceral leishmaniasis in endemic developing countries. Bulletin World Health Organ-ization, 76, 25–32.
   PubMed Web of Science ®Google Scholar
• Davidson, R. N., di Martino, L., Gradoni, L., Giacchino, R., Russo, R., Gaeta, G. B., Pempinello, R., Scott, S., Raimondi, F., Cascio, A., Prestileo, T., Caldeira, L., Wilkinson, R. J. & Bryceson, A. D. M. (1994). Liposomal amphotericin B(AmBisome) in Mediterranean visceral leish-maniasis: a multi-centre trial. Quarterly Journal of Medicine, 87, 75–81.
   Google Scholar
• Davidson, R. N., diMartino, L., Gradoni, L., Giacchino, R., Gaeta, G. B., Pempinello, R., Scott, S., Cascio, A., Castagnola, E., Maisto, A., Gramiccia, M., diCrapio, D., Wilkinson, J. R. & Bryceson, A. D. M. (1996). Short-course treatment of visceral leishmaniasis with liposomal amphotericin B(AmBisome). Clinical Infectious Diseases, 22, 938–943.
   Google Scholar
• Delgado, J., Macias, J., Pineda, J. A., Corzo, J. A., Gonzalez-Moreno, M. P., de la Rosa, R., Sanchez-Quijano, A., Leal, M. & Lissen, E. (1999). High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1 -infected patients. American Journal of Tropical Medicine and Hygiene, 61, 766–769.
   PubMed Web of Science ®Google Scholar
• Dellamonica, P., Bernard, E., Le Fichoux, Y., Politano, S., Carles, M. M., Durand, J. & Mondain, V. (1989). Allopurinol for treatment of visceral leishmaniasis in patients with AIDS. Journal of Infectious Diseases, 160, 904–905.
   PubMed Web of Science ®Google Scholar
• Górgolas, M., Castrillo, J. M. & Fernandez-Guerrero, M. L. (1994). Visceral leishmaniasis in patients with AIDS: report of three cases treated with pentavalent antimony and interferon y. Clinical Infectious Diseases, 17, 56–58.
   Google Scholar
• Herwaldt, B. L. & Berman, J. D. (1992). Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. American Journal of Tropical Medicine and Hygiene, 46, 296–306.
   PubMed Web of Science ®Google Scholar
• Janknegt, T., de Marie, S., Bakker-Woudenmberg, I. A. J. M. & Crommelin, D. J. A. (1992). Liposomal and lipid formulations of amphotericin B. Clinical Pharmacokinetics. Clinical Pharmacokinetics, 23, 279–291.
   PubMed Web of Science ®Google Scholar
• Jha, T. K., Sundar, S., Thakur, C. P., Bachmann, P., Karbwang, J., Fischer, C., Voss, A. & Berman, J. (1999). Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. New England Journal of Medicine, 341, 1795–1800.
   PubMed Web of Science ®Google Scholar
• Laguna, F., Lopez-Vélez, R., Soriano, V., Montilla, P., Alvar, J. & Gonzalez-Lahoz, J. M. (1994). Assess-ment of allopurinol plus meglumine antimoniate in the treatment of visceral leishmaniasis in patients with HIV. Journal of Infection, 28, 255–259.
   PubMed Web of Science ®Google Scholar
• Laguna, F., Torre-Cisneros, J., Moreno, V., Villanueva, J. L. & Valencia, E. (1995). Efficacy of intermittent liposomal amphotericin B in the treatment of visceral leishmaniasis in patients infected with HIV. Clinical Infectious Diseases, 21, 711–712.
   PubMed Web of Science ®Google Scholar
• Laguna, F., Adrados, M., Alvar, J., Soriano, V., Valencia, M. E., Moreno, V., Polo, R., Verdejo, J., Jimenez, M. I., Martinez, P., Martinez, M. L. & Gonzalez-Lahoz, J. M. (1997). Visceral leishmaniasis in patients infected with the human immuno-deficiency virus. European Journal of Clinical Micro-biology and Infectious Diseases, 16, 898–903.
   PubMed Web of Science ®Google Scholar
• Laguna, F., Lopez-Vélez, R., Pulido, F., Salas, A., Torre-Cisneros, J., Torres, J., Medrano, F. J., Sanz, J., PicO, G., Gomez-Rodrigo, J., Pasquau, J. & Alvar, J., for the Spanish HIV—Leishmania Study Group (1999). Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. AIDS, 13, 1063–1070.
   Google Scholar
• Laguna, F., Videla, S., Jimenez-Mejias, M. E., Sirera, G., Torre-Cisneros, J., Ribera, E., Prados, D., Clotet, B., Sust, M., LOpez-Velez, R. & Alvar, J., on behalf of the Spanish HIV —Leishmania Study Group (2003). Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study. Journal of Antimicrobial Chemotherapy, 52, 464–468.
   Google Scholar
• Lazanas, M. C., Tsekes, G. A., Papandreou, S., Harhalakis, N., Scandali, A., Nikiforakis, E. & Saroglou, G. (1993). Liposomal amphotericin B for leishmaniasis treatment of AIDS patients unresponsive to antimonium compounds. AIDS, 7, 1018-1019.
   Google Scholar
• López, M., Gil, A., Lavilla, P., Pintado, V., Valencia, E., Martinez, P. & Garcia-Puig, J. (1993). Efficacy of liposomal amphotericin B in the treatment and secondary prophylaxis of visceral leishmaniasis in HIV infected patients: report of two cases. Journal of Antimicrobial Chemotherapy, 32, 657–659.
   PubMed Web of Science ®Google Scholar
• López-Vélez, R., Perez-Molina, J. A., Guerrero, A., Baquero, F., Villarrubia, J., Escribano, L., Bellas, C., Perez-Corral, F. & Alvar, J. (1998). Clinic-epidemiologic characteristics, prognostic factors, and survival analysis of patients with human immuno-deficiency virus and Leishmania in an area of Madrid, Spain. American Journal of Tropical Medicine and Hygiene, 58, 436–443.
   PubMed Web of Science ®Google Scholar
• López-Vélez, R., Casado, J. L. & Pintado, V. (2001). Decline of visceral leishmaniasis epidemic in HIV-infected patients after the introduction of highly active antiretroviral therapy (HAART). Clinical Microbiology and Infection, 7, 394-395.
   Google Scholar
• Lortholary, O., Mechali, D., Christiaens, D., Gougerot, M., Brandel, M. & Babinet, P. (1990). Interferon 7 associated with convencional therapy for recurrent visceral leishmaniasis in a patients with AIDS. Review of Infectious Diseases, 12, 370–371.
   PubMedGoogle Scholar
• Medrano, F. J., Hernández-Quero, J., Jimenez, E., Pineda, J. A., Rivero, A., Sinchez-Quijano, A., Vélez, I. D., Vicaiana, P., Castillo, R., Reyes, M. J., Carvajal, F., Leal, M. & Lissen, E. (1992). Visceral leishmaniasis in HIV-1 infected individuals: a common opportunistic infection in Spain? AIDS, 6, 1499–1503.
   PubMed Web of Science ®Google Scholar
• Meyerhoff, A. (1999). U.S. Food and Drug Admini-stration approval of AmBisome (liposomal ampho-tericin B) for treatment of visceral leishmaniasis. Clinical Infectious Diseases, 28, 42–48.
   PubMed Web of Science ®Google Scholar
• Montalbán, C., Calleja, J. L., Erice, A., Laguna, F., Clotet, B., Podzamczer, D., Cobo, J., Mallolas, J., Yebra, M., Gallego, A. & the Co-operative Group for the Study of Leishmaniasis in AIDS. (1990). Visceral leishmaniasis in patients infected with human immunodeficiecy virus. Journal of Infection, 21, 161–170.
   Google Scholar
• Mora, A., Borrell, M., Galofré, J. & Grau, J. M. (1990). Alopurinol en el tratamiento de pacientes infectados por el VIH con leishmaniasis visceral. Enfernzedades Infecciosas y Microbiologia Clinica, 8,257–258.
   PubMedGoogle Scholar
• Morales, M. A., Chicharro, C., Calmvate, C., Barker, D. C. & Alvar, J. (2001). Molecular tracking of infections by Leishmania infantum. Transactions of the Royal Society of Tropical Medicine and Hygiene, 95, 104–107.
   PubMed Web of Science ®Google Scholar
• Mullen, A. B., Carter, K. C. & Baillie, A. J. (1997). Comparison of the efficacies of various formulations of amphotericin B againts murine visceral leish-maniasis. Antimicrobial Agents and Chemotherapy, 41, 2089–2092.
   PubMed Web of Science ®Google Scholar
• Murray, H. W. (2000). Treatment of visceral leish-maniasis (kala-azar): a decade of progress and future approaches. International Journal of Infectious Diseases, 4, 158–177.
   PubMedGoogle Scholar
• Pintado, V., Martin-Rabaddn, P., Rivera, M. L., Moreno, S. & Bouza, E. (2001). Visceral leish-maniasis in human-immunodeficiency virus (HIV)-infected and non HIV-infected patients. Medicine, 80, 54–73.
   PubMed Web of Science ®Google Scholar
• Ribera, E., Ocafia, I., Otero, J., Cortes, E., Gasser, I. & Pahissa, A. (1996). Prophylaxis of visceral leish-maniasis in human immunodeficiency virus-infected patients. American Journal of Medicine, 100, 496–501.
   PubMed Web of Science ®Google Scholar
• Rosenthal, E., Marty, P., Poizot-Martin, I., Reynes, J., Pratlong, F., Lafeuillade, A., Jaubert, D., Boulat, O., Dereure, J., Gambarelli, F., Gastaut, J. A., Dujardin, P., Dellamonica, P. & Cassuto, J. P. (1995). Visceral leishmaniasis and HIV-1 co-infection in southern France. Transactions of the Royal Society of Tropical Medicine and Hygiene, 89, 159–162.
   PubMed Web of Science ®Google Scholar
• Russo, R., Nigro, L. C., Minniti, S., Montineri, A., Gradoni, L., Caldeira, L. & Davidson, R. N. (1996). Visceral leishmaniasis in HIV infected patients with high dose liposomal amphotericin B (AmBisome). Journal of Infection, 32, 133–137.
   PubMed Web of Science ®Google Scholar
• Sundar, S. & Murray, H. W. (1996). Cure of antimony-unresponsive indian visceral leishmaniasis with ampho-tericin B lipid complex. Journal of Infectious Diseases, 173, 762–765.
   PubMed Web of Science ®Google Scholar
• Sundar, S., Agrawal, N. K., Sinha, P. R., Hoewith, G. S. & Murray, H. W. (1997). Short-course, low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony. Annals of Internal Medicine, 127, 133–137.
   PubMed Web of Science ®Google Scholar
• Torre-Cisneros, J., Villanueva, J. L., Kindelan, J. M., Jurado, R. & Sinchez-Guijo, P. (1993). Succesful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients with HIV. Clinical Infectious Diseases, 17, 625–627.
   PubMed Web of Science ®Google Scholar
• Tumbarello, M., Tacconelli, E., Bertagnolio, S. & Cauda, R. (2000). Highly active antiretroviral therapy decreases incidence of visceral leishmaniasis in HIV-infected individuals. AIDS, 14, 2948–2949.
   PubMed Web of Science ®Google Scholar